TGFB1 and acute myeloid leukemia: What’s more, for the different AML stages, TGF-β level was markedly decreased in ND and relapsed-refractory AML patients compared with the level in CR patients (median, 10443pg/ml; range, 6450.6–14436 pg/ml; ***P <0.0001; *P = 0.0007; respectively) (Fig 2F).